Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi Biologics to Partner with Toregem to Develop mAb for Tooth Regeneration

publication date: Oct 12, 2022

Shanghai WuXi Biologics and Toregem BioPharma, a Kyoto University biotech startup, signed a Memorandum of Understanding to partner development of TRG035, a monoclonal antibody targeting USAG-1 for congenital adentia. TRG035 is a tooth regeneration antibody drug based on the research results of Dr. Katsu Takahashi, Oral and Maxillofacial Surgery, Kyoto University. Although most adults have a full set of 32 teeth, about 1% of the population has more or fewer due to congenital conditions. USAG-1 is a bifunctional protein that antagonizes BMP and Wnt, two signaling molecules essential for tooth development. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital